CompletedNot applicableNCT01431326

Pharmacokinetics of Understudied Drugs Administered to Children Per Standard of Care

Understudied drugs will be administered to children per standard of care as prescribed by their treating caregiver and only biological sample collection during the time of drug administration will be involved. A total of approximately 7000 children aged \<21 years who are receiving these drugs for standard of care will be enrolled and will be followed for up a maximum of 90 days. The goal of this study is to characterize the pharmacokinetics of understudied drugs for which specific dosing recommendations and safety data are lacking. The prescribing of drugs to children will not be part of this protocol. Taking advantage of procedures done as part of routine medical care (i.e. blood draws) this study will serve as a tool to better understand drug exposure in children receiving these drugs per standard of care. The data collected through this initiative will also provide valuable pharmacokinetic and dosing information of drugs in different pediatric age groups as well as special pediatric populations (i.e. obese).

Checked against the public recordLast updated Sep 6, 2023 · Source: ClinicalTrials.gov

StatusCompleted
PhaseNot applicable
U.S. locations52
SponsorDaniel Benjamin
01
Study overview

What this study is about

Purpose
Not specified
Study type
Observational
Phase
Not applicable
Sponsor
Daniel Benjamin
Interventions being studied
Drug: The POPS study is collecting PK data on children prescribed the following drugs of interest per standard of care:
02
Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

03
Public criteria

Who may be able to participate

Inclusion Criteria: * 1\) Children (\< 21 years of age) who are receiving understudied drugs of interest per standard of care as prescribed by their treating caregiver Exclusion Criteria: * 1\) Failure to obtain consent/assent (as indicated) * 2\) Known pregnancy as determined via interview or testing if available.

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

04
Study sites

U.S. locations

  • Alaska Native Medical CenterAnchorage, Alaska
  • Arkansas Children's HospitalLittle Rock, Arkansas
  • University of California at San Diego Medical CenterLa Jolla, California
  • Axis Clinical TrialsLos Angeles, California
  • University of California, Los Angeles Medical CenterLos Angeles, California
  • The Children's Hospital ColoradoAurora, Colorado
  • Yale New Haven Children's HospitalNew Haven, Connecticut
  • Alfred I. DuPont Hospital for ChildrenWilmington, Delaware
  • Children's National Medical CenterWashington D.C., District of Columbia
  • University of Florida Jacksonville Shands Medical CenterJacksonville, Florida
  • Kapiolani Womens and Childrens Medical CenterHonolulu, Hawaii
  • Lurie Children's Hospital of ChicagoChicago, Illinois

Source and freshness
Processed from ClinicalTrials.gov. Last public update: Sep 6, 2023. Always confirm current availability with the study team.

View original record ↗